A Phase 4 interventional study of flotufolastat (18F) and piflufolastat (18F) in Prostate Cancer, sponsored by Blue Earth Diagnostics. Completed at 9 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Blue Earth Diagnostics (part of Bracco) · Phase 4, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing flotufolastat F 18 in Prostatic Neoplasms — 6 open to participants now, 7 under way, 2 of them phase 3. flotufolastat F 18 · Prostatic Neoplasms.
Among the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms, this one is the 9th largest by enrollment, is the only one that started in 2024, is the only one in phase 4, and was the 7th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →6 of the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+ · Men only
University of Florida · Sites in United States
Ages 18–100 · Men only
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18–90 · Men only
Hackensack Meridian Health · Sites in United States
Ages 18+ · Men only
Emory University · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 4 · Phase 4 1
First in 2019; this study’s year is marked. 1 started in 2024.
This study's enrollment of 62 is close to the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 70 across the 15 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Blue Earth Diagnostics, one of the names counted as Bracco. Under that name alone:
Blue Earth Diagnostics is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
13 studies in Prostatic Neoplasms by Bracco: 2 open now, 2 under way, none of them phase 3. Of 11 finished, 8 (73%) have results posted.
Among the 13 studies in Prostatic Neoplasms by Bracco, this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 2 in phase 4, and was the 12th registered.
Bracco’s Prostatic Neoplasms studies by the year they started, since 2009.
1 of the studies testing flotufolastat F 18 in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07285057Icahn School of Medicine at Mount SinaiDiagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms, from their registry updates:
Among Bracco’s 13 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men with Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
This is a multi-center, prospective intra-patient comparator study of urinary radioactivity (standardized uptake values [SUV]) following both piflufolastat (18F) and flotufolastat (18F) positron emission tomography (PET) in patients with low prostate-specific antigen (PSA; ≤0.5 ng/mL) biochemical recurrence (BCR) of prostate cancer following radical prostatectomy (RP).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each patient will be administered a single dose of piflufolastat (18F) on Day 1, followed by a PET scan. At least 24 hours after the piflufolastat (18F) scan, but within 10 calendar days, all patients will be administered a single dose of flotufolastat (18F) followed by a PET scan.
Drug: flotufolastat (18F) · Drug: piflufolastat (18F)
Positron emission tomography (PET)
Positron emission tomography (PET)
To Compare Urinary Bladder Radioactivity Observed on Piflufolastat (18F) PET and Flotufolastat (18F) PET.
Difference in urinary bladder mean SUV (SUVmean) between piflufolastat (18F) and flotufolastat (18F). A positive difference represents a lower bladder SUVmean for flotufolastat (18F) compared to piflufolastat (18F).
Time frame: piflufolastat (18F) administration and PET on Day 1; and flotufolastat (18F) administration and PET at least 24 hours after the piflufolastat (18F) scan but within 10 calendar days
Patient Level Detection Rates Following Piflufolastat (18F) PET and Flotufolastat (18F) PET
Defined as the total number of patients with at least one PET positive lesion / total number of patients.
Time frame: piflufolastat (18F) administration and PET on Day 1; and flotufolastat (18F) administration and PET at least 24 hours after the piflufolastat (18F) scan but within 10 calendar days
Patient Level Detection Rates Stratified by PSA Level Following Piflufolastat (18F) PET and Flotufolastat (18F) PET
Defined as the total number of patients with at least one PET positive lesion / total number of patients in PSA group.
Time frame: Screening, piflufolastat (18F) administration and PET on Day 1; and flotufolastat (18F) administration and PET at least 24 hours after the piflufolastat (18F) scan but within 10 calendar days
Detection Rate for Prostate Bed and Local Recurrences by Subregion Following for Piflufolastat (18F) PET and Flotufolastat (18F) PET
Time frame: Screening, piflufolastat (18F) administration and PET on Day 1; and flotufolastat (18F) administration and PET at least 24 hours after the piflufolastat (18F) scan but within 10 calendar days
Detection Rate for Pelvic Lymph Node (PLN) Following for Piflufolastat (18F) PET and Flotufolastat (18F) PET
Time frame: Piflufolastat (18F) administration and PET on Day 1; and flotufolastat (18F) administration and PET at least 24 hours after the piflufolastat (18F) scan but within 10 calendar days
| Milestone | Piflufolastat (18F) and Flotufolastat (18F) Positron Emission Tomography (PET) |
|---|---|
| Started | 62 |
| Completed | 55 |
| Not completed | 7 |
Difference in urinary bladder mean SUV (SUVmean) between piflufolastat (18F) and flotufolastat (18F). A positive difference represents a lower bladder SUVmean for flotufolastat (18F) compared to piflufolastat (18F).
| ratio | Piflufolastat (18F) PET | Flotufolastat (18F) PET |
|---|---|---|
| To Compare Urinary Bladder Radioactivity Observed on Piflufolastat (18F) PET and Flotufolastat (18F) PET. | 29.0 (18.9 to 40.8) | 10.9 (6.0 to 18.5) |
Defined as the total number of patients with at least one PET positive lesion / total number of patients.
| percentage of participants | Piflufolastat (18F) PET | Flotufolastat (18F) PET |
|---|---|---|
| Patient Level Detection Rates Following Piflufolastat (18F) PET and Flotufolastat (18F) PET | 27.3 (16.1 to 41.0) | 45.5 (32.0 to 59.4) |
Defined as the total number of patients with at least one PET positive lesion / total number of patients in PSA group.
| percentage of participants | Flotufolastat (18F) PET; PSA ≤ 0.2 ng/mL | Piflufolastat (18F) PET; PSA ≤ 0.2 ng/mL | Flotufolastat (18F) PET; PSA > 0.2 ng/mL | Piflufolastat (18F) PET; PSA > 0.2 ng/mL |
|---|---|---|---|---|
| Patient Level Detection Rates Stratified by PSA Level Following Piflufolastat (18F) PET and Flotufolastat (18F) PET | 52.4 (29.8 to 74.3) | 38.1 (18.1 to 61.6) | 41.2 (24.6 to 59.3) | 20.6 (8.7 to 37.9) |
| percentage of participants | Flotufolastat (18F) Positron Emission Tomography (PET) | Piflufolastat (18F) PET |
|---|---|---|
| Prostate Bed | 18.2 (9.1 to 30.9) | 10.9 (4.1 to 22.2) |
| Remnant Seminal Vesicles/Lateral Surgical Margin | 7.3 (2.0 to 17.6) | 3.6 (0.4 to 12.5) |
| Retrovesical | 3.6 (0.4 to 12.5) | 3.6 (0.4 to 12.5) |
| Vesicourethral Anastomosis | 7.3 (2.0 to 17.6) | 1.8 (0.0 to 9.7) |
| percentage of participants | Flotufolastat (18F) Positron Emission Tomography (PET) | Piflufolastat (18F) PET |
|---|---|---|
| Detection Rate for Pelvic Lymph Node (PLN) Following for Piflufolastat (18F) PET and Flotufolastat (18F) PET | 16.4 (7.8 to 28.8) | 14.5 (6.5 to 26.7) |
Collected over Adverse events were collected up to 10 days following administration of piflufolastat (18F) and up to 24 hours post administration of flotufolastat (18F). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Piflufolastat (18F) PET | 0/62 (0%) | 1/62 (1.6%) | 3/62 (4.8%) |
| Flotufolastat (18F) PET | 0/57 (0%) | 0/57 (0%) | 2/57 (3.5%) |
| Event | Piflufolastat (18F) PET | Flotufolastat (18F) PET |
|---|---|---|
| Extortional dyspnoeaRespiratory, thoracic and mediastinal disorders | 1/62 | 0/57 |
| Event | Piflufolastat (18F) PET | Flotufolastat (18F) PET |
|---|---|---|
| Abdominal DiscomfortGastrointestinal disorders | 0/62 | 1/57 |
| DiarrheaGastrointestinal disorders | 1/62 | 1/57 |
| Taste DisorderNervous system disorders | 0/62 | 1/57 |
| FatigueGeneral disorders | 1/62 | 0/57 |
| Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders | 1/62 | 0/57 |
| FlushingVascular disorders | 1/62 | 0/57 |
| Age, Categorical(Participants) | Piflufolastat (18F) and Flotufolastat (18F) Positron Emission Tomography (PET) |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 15 |
| >=65 years | 40 |
| Sex: Female, Male(Participants) | Piflufolastat (18F) and Flotufolastat (18F) Positron Emission Tomography (PET) |
|---|---|
| Female | 0 |
| Male | 55 |
| Ethnicity (NIH/OMB)(Participants) | Piflufolastat (18F) and Flotufolastat (18F) Positron Emission Tomography (PET) |
|---|---|
| Hispanic or Latino | 5 |
| Not Hispanic or Latino | 50 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Piflufolastat (18F) and Flotufolastat (18F) Positron Emission Tomography (PET) |
|---|---|
| Race — White | 44 |
| Race — Black or African American | 4 |
| Race — Asian | 3 |
| Race — Not Reported | 1 |
| Race — Unknown | 2 |
| Race — Other | 1 |
| Baseline Weight(kg) | Piflufolastat (18F) and Flotufolastat (18F) Positron Emission Tomography (PET) |
|---|---|
| Mean | 90.0 ± 16.60 |
| Baseline Height(cm) | Piflufolastat (18F) and Flotufolastat (18F) Positron Emission Tomography (PET) |
|---|---|
| Mean | 177.3 ± 7.70 |
| Baseline Body Mass Index (kg/m2)(Kg/m2) | Piflufolastat (18F) and Flotufolastat (18F) Positron Emission Tomography (PET) |
|---|---|
| Mean | 28.6 ± 4.66 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2024 to primary completion in Aug 2025, 8 months.
Results were first posted in May 2026, 8 months after primary completion.
Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Flotufolastat F 18 · Piflufolastat